Peripheral T-cell Lymphoma Clinical Trials

252 clinical trials for Peripheral T-cell Lymphoma across international registries, including 46 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) — RECRUITING
• Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma — RECRUITING · PHASE1
• A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma — RECRUITING · NA
• To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL — RECRUITING · PHASE3
• Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas — RECRUITING · PHASE1
• A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) — RECRUITING · PHASE1
• Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma — RECRUITING · PHASE1
• Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies — RECRUITING · PHASE1
• AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. — RECRUITING · PHASE1
• A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) — RECRUITING · PHASE3
• Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution — RECRUITING
• Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma — RECRUITING · PHASE2
• Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies — RECRUITING · PHASE1
• Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma — RECRUITING · PHASE2
• Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study — RECRUITING
• T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR — RECRUITING
• Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy — RECRUITING · PHASE3
• A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study — RECRUITING · PHASE2
• A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma — RECRUITING · PHASE2
• Evaluate the Safety and Clinical Activity of HH2853 — RECRUITING · PHASE1
• T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR — RECRUITING
• Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma — RECRUITING · PHASE1
• Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR) — RECRUITING
• Amping up With PemJAK — RECRUITING · PHASE2
• Linperlisib Combined With Chidamide in Patients With PTCL — RECRUITING · PHASE1
• Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma — RECRUITING · PHASE1
• BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas — RECRUITING · PHASE3
• CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma — RECRUITING · PHASE2
• Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma — RECRUITING · PHASE1
• Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients — RECRUITING · NA
• AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS — RECRUITING · PHASE1
• GVM±R in Patients With Relapsed or Refractory Aggressive NHL. — RECRUITING · PHASE2
• Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. — RECRUITING
• A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies — RECRUITING · PHASE1
• Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma — RECRUITING · PHASE2
• Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma — RECRUITING · PHASE2
• Golidocitinib Plus CHOP in Newly Diagnosed PTCL — RECRUITING · PHASE1
• A PHASE 3, RANDOMIZED, OPEN LABEL STUDY TO INVESTIGATE THE EFFICACY AND STAFETY OF ITK INHIBITOR SOQUELITINIB VERSUS PHYSICIAN'S CHOICE STANDARD OF CARE TREATMENT (SELECTED SINGLE AGENT) IN PARTICIPANTS WITH RELAPSED/REFRACTORYPERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED ,FOLLICULAR HELPER T-CELL LYMPHOMAS,OR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA — RECRUITING · PHASE3
• PHASE 1B, RANDOMIZED, DOSE OPTIMIZATION STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY, SAFETY, AND PHARMACOKINETICS OF TLN-254 IN PATIENTS WITH RELAPSED OR REFRACTORY T-CELL LYMPHOMA — RECRUITING · PHASE1
• Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma — RECRUITING · PHASE1
• A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF THE COMBINATION OF BELEODAQ-CHOP OR FOLOTYN-COP TO THE CHOP REGIMEN ALONE IN NEWLY DIAGNOSED PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA — RECRUITING · PHASE3
• Genotype-guided Treatment in Newly Diagnosed PTCL — RECRUITING · PHASE1
• Transplantation After Complete Response In Patients With T-cell Lymphoma — RECRUITING · NA
• Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma — RECRUITING · PHASE2
• "A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, ETOPOSIDE, AND PREDNISONE (CHEP-BV) FOLLOWED BY BV CONSOLIDATION IN PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS." — RECRUITING · PHASE2
• Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies — COMPLETED · PHASE1
• A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression — COMPLETED · PHASE2
• The Efficacy of CAPCT in Patients With PTCL — NOT_YET_RECRUITING · PHASE2
• A Phase 2/3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma — TERMINATED · PHASE3

Refine this search